In particular, the feasibility of BCR-ABL1 exosomal transcript detection in CML patients in the chronic phase, under treatment and with an undetectable level of MRD, has been reported [108]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.